Alzheimer’s disease: Modeling current and potential targets
By the time we are 65, one in ten of us will have contracted Alzheimer’s disease. This rises to fifty ...
In this article, published in the autumn 2012 issue of Innovations in Pharmaceutical Technology, Rob Scoffin (Cresset’s CEO) explores the chemical space around existing drug molecules to provide a lower-risk, lower-cost strategy for the discovery of new chemical entities.
Click below to read full article.